| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | D Matthew Shoemaker | |
| Jikerkhoun Simou | |||
| William E Roland | |||
| P2860 | cites work | The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species | Q44477178 |
| Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide | Q44574430 | ||
| Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms | Q44777352 | ||
| Moderate liver impairment has no influence on daptomycin pharmacokinetics | Q44938154 | ||
| Muscle pain associated with daptomycin | Q45059184 | ||
| The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects | Q45188826 | ||
| Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin | Q45221988 | ||
| Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections | Q45230598 | ||
| Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis | Q45275757 | ||
| Severe myopathy and possible hepatotoxicity related to daptomycin | Q45295722 | ||
| Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. | Q46433642 | ||
| Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
| Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection | Q46607570 | ||
| Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia | Q46716065 | ||
| Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. | Q54034073 | ||
| Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers | Q24679375 | ||
| Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits | Q30451719 | ||
| Development of daptomycin for gram-positive infections | Q33920377 | ||
| In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model | Q33980074 | ||
| Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi | Q33981366 | ||
| Resistance studies with daptomycin | Q33982318 | ||
| Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center | Q34270638 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections | Q34393212 | ||
| Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy | Q36257693 | ||
| Population pharmacokinetics of daptomycin | Q36670451 | ||
| Daptomycin disrupts membrane potential in growing Staphylococcus aureus | Q36756893 | ||
| Once-daily dosing in dogs optimizes daptomycin safety | Q39537062 | ||
| Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis | Q40166184 | ||
| Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model | Q40345387 | ||
| Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy | Q42708842 | ||
| Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates | Q42925097 | ||
| Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint | Q43753597 | ||
| In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium | Q43786344 | ||
| In vitro bactericidal activity of daptomycin against staphylococci | Q43895572 | ||
| P433 | issue | 2 | |
| P921 | main subject | (2S)-daptomycin | Q63413234 |
| P304 | page(s) | 169-174 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections | |
| P478 | volume | 2 |
| Q93165353 | Antibacterial Activity of Rationally Designed Antimicrobial Peptides |
| Q38202581 | Antimicrobial agents, drug adverse reactions and interactions, and cancer |
| Q44738071 | Daptomycin for the treatment of gram-positive infections after cardiac surgery |
| Q37150644 | Daptomycin for the treatment of major gram-positive infections after cardiac surgery. |
| Q36868647 | Genetic mechanisms of antimicrobial resistance identified in Salmonella enterica, Escherichia coli, and Enteroccocus spp. isolated from U.S. food animals |
| Q37954604 | The potential of antimicrobial peptides as biocides |
| Q38515064 | Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles |
Search more.